Brief: Xbiotech Inks Clinical Manufacturing Deal
02/02/2022 16:38
Xbiotech Inc XBIT.O :
* XBIOTECH INKS CLINICAL MANUFACTURING DEAL
* EXECUTED MANUFACTURING AGREEMENT WITH JANSSEN RESEARCH &
DEVELOPMENT, LLC
* XBIOTECH-AGREEMENT TO MANUFACTURE CLINICAL PRODUCT,
INCLUDING
BERMEKIMAB, TRUE HUMAN MONOCLONAL ANTIBODY SOLD TO JANSSEN BY
XBIOTECH IN DECEMBER 2019
* NEW AGREEMENT WILL EXTEND XBIOTECH'S MANUFACTURING SUPPORT
UNTIL
DECEMBER, 2023
Source text for Eikon: ID:nGNX4Zs5h3
Further company coverage: XBIT.O
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke